兴科蓉医药(06833)发布中期业绩 股东应占溢利2438.9万元 同比增加2.17%

Core Viewpoint - Xinkelong Pharmaceutical (06833) reported a net profit attributable to shareholders of 24.39 million yuan, reflecting a year-on-year increase of 2.17% despite a revenue decline of 21.68% to 1.196 billion yuan for the six months ending June 30, 2025 [1] Financial Performance - The company achieved revenue of 1.196 billion yuan, which represents a decrease of 21.68% compared to the previous year [1] - The net profit attributable to shareholders was 24.39 million yuan, showing a year-on-year increase of 2.17% [1] - Basic earnings per share were reported at 0.012 yuan [1]